Parkman Healthcare Partners LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001777015

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2026 · 90 positions · Total reported value $1.11B · Top-10 concentration 32.5% · Updated 2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

Turnover: 68.0% · 26 new · 31 cut · 13 exited

Active Share (vs S&P 500): 97.4% · vs QQQ: 99.7% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -2.8% · vs SPY -4.9% · Prev Value $976.83M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -1.8% · vs SPY -4.0% · Latest Value $1.11B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Parkman Healthcare Partners LLC disclosed 90 equity positions with a combined reported value of $1.11B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 32.5% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were PTCT ($45.37M), LLY ($44.11M), MBX ($42.00M). By sector, the heaviest allocations are Health Care 95.2%, Consumer Staples 2.2%. Versus the prior quarter, allocation shifted toward Health Care (+3.1pp) and away from Industrials (-1.8pp), Consumer Staples (-1.9pp).

Versus the prior quarter, Parkman Healthcare Partners LLC opened 26 new positions, trimmed 31 and fully exited 13, a turnover rate of 68.0% of positions. The portfolio's overlap with the prior quarter was 62% of names.

The largest new positions opened in Q3 2026 were SRRK ($26.09M), CRL ($17.70M), KOD ($17.63M).

Of the 13 positions fully exited versus the prior quarter, the largest were SYK ($21.40M), ZBH ($20.02M), BCRX ($16.24M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • SRRK SCHOLAR ROCK HLDG CORP · $26.09M
  • CRL CHARLES RIV LABS INTL INC · $17.70M
  • KOD KODIAK SCIENCES INC · $17.63M
  • ABT ABBOTT LABORATORIES · $16.33M
  • WST WEST PHARMACEUTICAL SVSC INC · $14.83M
  • ATRC ATRICURE INC · $12.66M
  • INSM INSMED INC · $11.99M
  • SDGR SCHRODINGER INC · $11.64M

Fully Exited (vs previous quarter)

  • SYK STRYKER CORPORATION · prev qtr: $21.40M
  • ZBH ZIMMER BIOMET HOLDINGS INC · prev qtr: $20.02M
  • BCRX BIOCRYST PHARMACEUTICALS INC · prev qtr: $16.24M
  • QURE UNIQURE NV · prev qtr: $9.59M
  • AMRX AMNEAL PHARMACEUTICALS INC · prev qtr: $9.37M
  • BSX BOSTON SCIENTIFIC CORP · prev qtr: $7.70M
  • RMD RESMED INC · prev qtr: $6.43M
  • ALGN ALIGN TECHNOLOGY INC · prev qtr: $6.23M

Insider Transactions (Form 4)

Latest Parkman Healthcare Partners LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Parkman Healthcare Partners LLC, based in Stamford, CT, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 77 positions worth $976.83M in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: STAMFORD, CT, United States
  • SEC registration: 801-114849 (status: Approved), registered 2019-03-15
  • Regulatory AUM (Form ADV): $1.74B as of 2026-03-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 1 private funds, of which 1 hedge funds

Portfolio Structure

  • 77 positions · $976.83M reported value (Q2 2026)
  • Top 10 holdings = 33.5% of reported value
  • Largest position: MBX (MBX BIOSCIENCES INC COM) at 4.5%
  • Average position size: $12.69M

Sector Tilt

  • Health Care 92.1%
  • Consumer Staples 4.1%
  • Industrials 3.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 18 new, 25 added, 30 reduced, 31 exited
  • 4 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund is actively increasing exposure to biotech/therapeutics (PTCT, IQV, INBX, VRDN, URGN, SRRK) while trimming larger-cap healthcare (MBX, DXCM) and consumer staples (CVS), suggesting a bullish stance on innovative healthcare and a preference for growth-oriented names. 2. Key moves: - Added: PTCT (+60.8% shares), IQV (+37.2%), INBX (+40.2%), VRDN (+21.6%), URGN (+331.0%), SRRK (new). - Reduced: MBX (-10.5%), DXCM (-18.3%), CVS (-26.9%), LLY (-8.9% shares). 3. Portfolio structure: Active, concentrated (top 10 = 29.2%), heavily biased toward Health Care (90%), with high risk appetite (small/mid-cap biotech focus). 4. Per-holding one-liner: - PTCT: Biotech (gene therapies) - LLY: Big Pharma (diabetes/oncology) - MBX: Biotech (cancer therapeutics) - IQV: Healthcare data/analytics - DXCM: Medical devices (diabetes monitoring) - INBX: Biotech (cancer therapeutics) - VRDN: Biotech (thyroid disease) - URGN: Biotech (urology) - SRRK: Biotech (muscle disorders) - CVS: Consumer Staples (pharmacy/retail) 5. Style summary: Aggressive biotech tilt with selective cuts in large-cap healthcare and consumer staples.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 04:41

Sector Allocation

Health Care 95.2%
Technology 0.8%
Other 0.2%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 700.39K $45.37M 4.09%
4.09%
Add
2 38.12K $44.11M 3.98%
3.98%
Add
3 716.54K $42.00M 3.79%
3.79%
Reduce
4 145.22K $39.04M 3.52%
3.52%
Add
5 437.03K $37.71M 3.40%
3.40%
Reduce
6 360.26K $36.05M 3.25%
3.25%
Add
7 1.67M $34.48M 3.11%
3.11%
Add
8 750.20K $30.48M 2.75%
2.75%
Add
9 540.00K $26.09M 2.35%
2.35%
New
10 286.29K $24.53M 2.21%
2.21%
Reduce
11 948.86K $24.22M 2.19%
2.19%
Add
12 633.31K $21.06M 1.90%
1.90%
Reduce
13 1.11M $20.78M 1.88%
1.88%
Add
14 55.87K $20.51M 1.85%
1.85%
Hold
15 675.10K $19.65M 1.77%
1.77%
Add
16 796.26K $18.70M 1.69%
1.69%
Add
17 521.58K $18.70M 1.69%
1.69%
Add
18 60.00K $17.70M 1.60%
1.60%
New
19 186.00K $17.63M 1.59%
1.59%
New
20 675.52K $17.45M 1.57%
1.57%
Reduce
21 600.05K $17.34M 1.56%
1.56%
Add
22 213.40K $16.77M 1.51%
1.51%
Add
23 165.18K $16.33M 1.47%
1.47%
New
24 63.85K $16.32M 1.47%
1.47%
Reduce
25 1.64M $15.70M 1.42%
1.42%
Reduce
26 195.56K $14.96M 1.35%
1.35%
Reduce
27 40.00K $14.83M 1.34%
1.34%
New
28 929.43K $14.25M 1.29%
1.29%
Add
29 1.13M $13.98M 1.26%
1.26%
Add
30 726.86K $13.74M 1.24%
1.24%
Add
31 185.85K $13.50M 1.22%
1.22%
Reduce
32 327.95K $13.31M 1.20%
1.20%
Reduce
33 367.91K $13.07M 1.18%
1.18%
Add
34 200.41K $13.03M 1.18%
1.18%
Reduce
35 225.25K $12.66M 1.14%
1.14%
New
36 27.88K $12.25M 1.11%
1.11%
Reduce
37 105.06K $11.99M 1.08%
1.08%
New
38 678.57K $11.81M 1.07%
1.07%
Add
39 375.00K $11.64M 1.05%
1.05%
New
40 50.07K $11.59M 1.05%
1.05%
New
41 772.18K $11.05M 1.00%
1.00%
Reduce
42 779.76K $10.97M 0.99%
0.99%
Add
43 329.25K $10.15M 0.92%
0.92%
Add
44 85.74K $9.75M 0.88%
0.88%
Add
45 130.00K $9.02M 0.81%
0.81%
New
46 110.00K $9.01M 0.81%
0.81%
New
47 425.35K $8.98M 0.81%
0.81%
New
48 283.76K $8.87M 0.80%
0.80%
Reduce
49 275.83K $8.83M 0.80%
0.80%
Add
50 35.16K $8.68M 0.78%
0.78%
Reduce

FAQ

What did Parkman Healthcare Partners LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, Parkman Healthcare Partners LLC reported 90 equity positions worth $1.11B in aggregate; its largest disclosed positions were PTCT ($45.37M), LLY ($44.11M), MBX ($42.00M).

How large is Parkman Healthcare Partners LLC's portfolio?

Parkman Healthcare Partners LLC reported $1.11B of long equity holdings across 90 positions as of 2026-Q3. Top-10 holdings account for 32.5% of reported value.

What is Parkman Healthcare Partners LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/parkman-healthcare-partners/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →